Cardamom And Liver Function-what Studies Actually Say
- 01. What the Science Says About Cardamom and Liver Function
- 02. Key Human Clinical Trials on Cardamom and Liver Markers
- 03. Animal Studies Linking Cardamom to Hepatic Protection
- 04. Mechanisms: How Cardamom Might Influence the Liver
- 05. Summary of Observed Effects in NAFLD and Preclinical Models
- 06. Practical Considerations for Using Cardamom
- 07. Limitations and Gaps in the Evidence
- 08. Takeaways for Clinicians and Health-Conscious Readers
- 09. Future Directions and Research Needs
What the Science Says About Cardamom and Liver Function
Human and animal studies indicate that cardamom supplementation can favorably modulate key liver enzymes, reduce hepatic inflammation, and improve markers of non-alcoholic fatty liver disease (NAFLD). In a 2018 randomized, double-blind, placebo-controlled trial on 87 overweight or obese NAFLD patients, green cardamom (green cardamom; 1.5 g/day for 3 months) significantly lowered alanine transaminase (ALT), high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6), while increasing Sirtuin-1, a longevity-linked protein implicated in hepatic insulin sensitivity. These findings suggest that cardamom may support liver health in metabolic-syndrome-related fatty liver, though the total body of evidence remains modest and is not yet sufficient to justify cardamom as a standalone treatment.
Key Human Clinical Trials on Cardamom and Liver Markers
In 2017, researchers in Tehran designed a randomized controlled trial protocol testing green cardamom capsules (2 x 500 mg with meals, three times daily for 3 months) in 80 obese NAFLD patients diagnosed by hepatic ultrasound. They planned to measure liver enzymes (ALT, aspartate transaminase [AST]), lipids, inflammatory markers, and adipokines such as irisin and Sirtuin-1, aiming to quantify how cardamom supplementation affects the full spectrum of NAFLD-related metabolic dysfunction. The protocol highlighted cardamom's prior animal-study benefits on hepatomegaly and dyslipidemia, but explicitly noted that no human data on NAFLD existed at the time, underscoring the novelty of the planned intervention.
The 2018 follow-up trial, published in Nutrition & Metabolism (London), randomly assigned 87 NAFLD patients to either green cardamom (43 participants) or placebo (44) for 3 months in the same hospital-based cohort. After the intervention, the cardamom group showed a statistically significant rise in Sirtuin-1 and a drop in hs-CRP, TNF-α, and IL-6, along with a reduction in ALT and sonographic fatty liver grade. Weight, body mass index (BMI), and AST did not change significantly versus placebo, suggesting that cardamom's main effect lies in dampening chronic inflammation and improving specific hepatic biomarkers rather than driving broad weight loss.
Animal Studies Linking Cardamom to Hepatic Protection
In a 2017 rat model, investigators fed high-carbohydrate, high-fat (HCHF) diets to induce hepatic steatosis and then added cardamom powder to the diet. The cardamom-supplemented animals developed less abdominal fat, improved glucose tolerance, and substantially lower plasma and liver markers of oxidative stress (lipid peroxidation, advanced protein oxidation products) than controls. Histological examination revealed less fat droplet accumulation and fewer inflammatory cells in the cardamom group, and plasma ALT, AST, and alkaline phosphatase (ALP) were normalized toward control levels, indicating protection against hepatic injury.
Additional rodent work combining ginger and cardamom extracts in high-fat-diet models showed that both spices individually reduced liver triglycerides, body-weight gain, and ALT/AST versus high-fat controls. However, the combination of ginger and cardamom appeared to produce the strongest attenuation of liver fat accumulation and inflammatory infiltration, hinting at synergistic mechanisms involving antioxidant pathways and insulin signaling. These data reinforce the idea that cardamom's bioactive compounds may help stabilize hepatic redox balance under metabolic stress.
Mechanisms: How Cardamom Might Influence the Liver
Cardamom's volatile oils and phenolic compounds-such as 1,8-cineole, terpinyl acetate, and flavonoids-have demonstrated in vitro and in vivo antioxidant and anti-inflammatory activity. In the context of liver tissue, these constituents may blunt nuclear factor-kappa B (NF-κB)-driven inflammation, reduce cytokine production, and upregulate endogenous antioxidant enzymes such as superoxide dismutase and catalase. In the 2018 NAFLD trial, the observed rise in Sirtuin-1 (a deacetylase enzyme tied to mitochondrial health and insulin sensitivity) suggests that cardamom may also modulate epigenetic regulators of hepatic metabolism.
Parallel research on cardamom and metabolic syndrome has reported modest improvements in lipid profiles, irisin, and paraoxonase-1 (PON1), a high-density lipoprotein-associated enzyme that protects against oxidative LDL modification. Because dyslipidemia and systemic inflammation are major drivers of NAFLD progression to steatohepatitis (NASH) and fibrosis, these systemic effects may indirectly support liver health by reducing the metabolic burden on hepatocytes. Nevertheless, most mechanistic evidence comes from animal or cell-based studies, so direct translation to human hepatic pathophysiology remains inferential.
Summary of Observed Effects in NAFLD and Preclinical Models
The following table synthesizes major outcomes from representative studies on cardamom and liver function (values are illustrative but directionally consistent with published data):
| Study type | Population | Cardamom dose | Key liver-related findings |
|---|---|---|---|
| Human RCT (2018) | 87 overweight/obese NAFLD patients | Green cardamom 1.5 g/day for 3 months | ↑ Sirtuin-1; ↓ hs-CRP, TNF-α, IL-6; ↓ ALT and fatty liver grade on ultrasound; no change in AST or BMI |
| Rat HCHF model (2017) | Rats fed high-carb, high-fat diet | Cardamom powder added to diet (≈ equivalent to 1-2% of diet weight) | ↓ Hepatic fat deposition and inflammatory infiltration; ↓ plasma ALT, AST, ALP; ↓ lipid peroxidation and protein oxidation; improvement in glucose tolerance |
| High-fat + spice combo (rodent) | Rats on high-fat diet with ginger and/or cardamom | Cardamom extract alone or combined with ginger | Cardamom alone reduced liver triglycerides and ALT/AST; combination with ginger showed strongest effect on liver fat and inflammation |
Across models, cardamom intake is consistently associated with reductions in markers of oxidative liver stress and inflammation, with more modest or nil effects on body weight or some traditional liver enzymes. This pattern supports the hypothesis that cardamom acts primarily as a hepatic modulator within broader lifestyle interventions rather than as a weight-loss agent.
Practical Considerations for Using Cardamom
Culinary use of whole cardamom pods or ground cardamom in teas, curries, and desserts falls well below the pharmacologic doses tested in clinical trials and is generally regarded as safe for most adults. A typical dietary pattern might include 0.5-1.0 g of ground cardamom per day, far lower than the 3 g/day capsule dose used in the NAFLD study. To support liver health within a broader strategy, individuals might consider using cardamom as part of a Mediterranean-style diet rich in fiber, unsaturated fats, and phytonutrient-dense spices, while avoiding excessive sugar and saturated fat.
Limitations and Gaps in the Evidence
Several limitations constrain how strongly the current data can be interpreted for cardamom and liver function. Most human evidence comes from a single medium-sized trial in a specific Iranian occupational cohort, limiting generalizability across ethnicities and healthcare systems. The animal studies use different doses, delivery methods (powder vs. extract), and diet models, making direct comparison difficult. Long-term safety, effects on liver fibrosis stage, and mortality outcomes remain unexamined, and cardamom has not been compared head-to-head with established lifestyle interventions or pharmacologic NAFLD therapies.
Takeaways for Clinicians and Health-Conscious Readers
For readers asking "scientists tested cardamom on liver health-results?", the synthesized evidence can be distilled into three points: (1) green cardamom appears to reduce ALT and inflammatory markers in overweight/obese NAFLD patients; (2) animal models show protection against hepatic steatosis, oxidative stress, and early fibrosis; and (3) cardamom should be viewed as a possible adjunct to, not a substitute for, standard care for liver disease. Future research should examine higher-dose formulations, longer durations, and hard endpoints such as fibrosis regression or progression to cirrhosis, but current data already support cardamom as a candidate nutraceutical worthy of further investigation in hepatology.
Future Directions and Research Needs
Upcoming trials listed in clinical-trial registries hint at deeper exploration of cardamom's metabolic effects, including larger NAFLD cohorts and trials combining cardamom with other spices or lifestyle-modification programs. Researchers are also beginning to analyze how cardamom influences gut-liver axis mediators such as bile acids and microbiota, since changes in gut health may influence hepatic inflammation. Until those data mature, the most prudent approach is to frame cardamom as an evidence-informed, low-risk dietary element that may complement-but not replace-standard medical care for liver dysfunction.
Everything you need to know about Scientific Studies On Cardamom And Liver Function
Does cardamom improve liver enzyme tests in humans?
Yes, in controlled human trials, green cardamom supplementation has lowered alanine transaminase (ALT) and reduced inflammatory markers in NAFLD patients, suggesting improved hepatic enzyme profiles. However, AST and most anthropometric measures did not change significantly versus placebo, indicating that cardamom's effect is selective and should be viewed as adjunctive to diet, exercise, and medical management rather than a replacement for them.
Can cardamom reverse non-alcoholic fatty liver disease?
Current science does not show that cardamom alone can fully reverse non-alcoholic fatty liver disease; it instead modestly improves several biomarkers and reduces ultrasound-detected fatty liver grade. In both human and animal studies, the most meaningful improvements occur when cardamom is combined with a healthier diet and physical activity, emphasizing that it should be considered a supportive nutraceutical strategy rather than a cure.
Is cardamom safe for people with existing liver disease?
There is limited long-term safety data for high-dose cardamom supplementation in individuals with advanced liver disease, despite rodent evidence of protective effects at moderate doses. In humans, typical culinary use is considered safe, but concentrated extracts or capsules could interact with liver metabolism via cytochrome P450 enzymes or other pathways. Anyone with hepatitis, cirrhosis, or abnormal liver function tests should consult a physician before adding medicinal-dose cardamom.
How much cardamom is used in the clinical studies?
In the 2018 NAFLD trial, participants received 2 x 500 mg green cardamom capsules three times daily (total 3 g/day as capsules) for 3 months. In animal models, cardamom powder was typically administered at 1-2% of total dietary weight, which translates to a much higher milligram-per-kilogram dose than human cooking amounts. These doses exceed typical dietary intake, so extrapolating cautiously to culinary use is important.